CTOs on the Move


 
Xena Health is a Hartford, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Life Care Centers of America

Since our first facility opened in 1970, Life Care`s associates have positively impacted the company`s mission of providing exceptional patient care. Life Care owns or manages more than 200 facilities and employs approximately 40,000 individuals who strive daily to make a difference in the lives of those we serve. Our facilities offer multiple levels of patient care and services, which vary by location. We offer post-acute care and inpatient and outpatient therapy in well-equipped, on-site rehabilitation gyms. We believe that as a privately owned company, Life Care Centers of America stands apart from others. We offer a resident-centered corporate culture with more than 45 years of experience, stability and success. Our modern and well-maintained facilities feature strong multidisciplinary teams, specialty programs and opportunities for continuing education.

Excerpta Medica

Excerpta Medica is a Bridgewater, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MedVet Medical & Cancer Centers for Pets

MedVet Medical & Cancer Centers for Pets has 5 different locations: MedVet Columbus 300 E. Wilson Bridge Rd. Wothington, OH 43085 614-846-5800 800-891-9010 MedVet Cincinnati 3964 RedBank Rd. Fairfax, OH 45227 513-561-0069 877-841-5818 ...

Jenson Medical International

Jenson Medical International is a Conroe, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kolltan

Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.